NETRF Clinical Trial Roundup: March 2026; Clinical Trials Highlight Advances in Neuroendocrine Tumor Research
Published: 01 Apr 2026
Author: Precedence Research
In March 2026, the Neuroendocrine Tumor Research Foundation (NETRF) released its latest clinical trial roundup, showcasing significant progress in neuroendocrine tumor (NET) research and offering new hope for patients worldwide.
One of the most notable updates comes from the Phase 3 COMPETE trial, which evaluated ITM-11 (177Lu-edotreotide), a radiopharmaceutical therapy developed by ITM Isotope Technologies Munich. The trial focused on patients with inoperable or progressive grade 1 or 2 gastroenteropancreatic NETs (GEP-NETs), enrolling 309 participants who were randomly assigned to receive either ITM-11 or the targeted therapy everolimus. In a subgroup of 178 participants with pancreatic NETs (Pan-NETs), ITM-11 demonstrated a median progression-free survival of 24.5 months, compared to 14.7 months with everolimus. The therapy also achieved a higher objective response rate, with 33.3% of patients showing measurable responses versus 3.6% for everolimus. These findings, presented at the 2026 Annual Meeting of the European Neuroendocrine Tumor Society (ENETS), suggest ITM-11 could offer meaningful improvements in patient outcomes.
On the regulatory front, the U.S. Food and Drug Administration (FDA) granted tentative approval to Lantheus’ PNT2003, a therapy designed to be radioequivalent to LUTATHERA®, an FDA-approved PRRT for NETs. While PNT2003 cannot yet be marketed due to patent-related protections in place through June 2026, final approval would provide an additional PRRT option for patients, potentially increasing access to life-changing treatments.
Emerging cell-based therapies are also showing promise. A Phase 1/2 trial of CHM CDH17, a CAR T-cell therapy developed by Chimeric Therapeutics, has advanced to a higher dose level following encouraging early results. The therapy targets the CDH17 cell surface protein and is being tested in participants with advanced gastrointestinal cancers, including intestinal NETs. Initial findings indicated no significant safety concerns or off-target effects, with some patients experiencing disease control and anti-tumor activity. The study is now evaluating a higher dose to determine the optimal Phase 2 regimen.
Together, these clinical developments reflect a rapidly evolving landscape in NET research. Advances in radiopharmaceutical therapies, regulatory milestones, and innovative CAR T-cell approaches are expanding treatment options and improving the potential for better outcomes. As trials progress and new therapies reach regulatory approval, patients living with neuroendocrine tumors may soon benefit from more effective, targeted, and accessible treatments.
We focus exclusively on this industry and provide insights that help you make better decisions. Get in touch to learn more@ https://www.precedenceresearch.com/clinical-trials-market